David T Teachey Selected Research

Cytokine Release Syndrome

1/2022	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
1/2022	Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.
10/2021	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
1/2021	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.
1/2021	Skewed Cytokine Responses Rather Than the Magnitude of the Cytokine Storm May Drive Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children.
12/2020	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
10/2020	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.
1/2020	Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.
1/2019	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
1/2019	Cellular therapy: Immune-related complications.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David T Teachey Research Topics

Disease

41	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 07/2005
23	Neoplasms (Cancer) 01/2022 - 06/2009
21	Cytokine Release Syndrome 01/2022 - 04/2013
14	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2022 - 12/2016
13	Leukemia 01/2022 - 10/2012
10	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 08/2007
8	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 10/2012
8	Cytopenia 09/2016 - 12/2009
7	Autoimmune Lymphoproliferative Syndrome 01/2020 - 09/2006
6	Macrophage Activation Syndrome 12/2021 - 02/2014
5	COVID-19 05/2021 - 01/2020
5	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2016 - 08/2007
4	Infections 05/2021 - 07/2005
4	Critical Illness (Critically Ill) 11/2020 - 01/2016
4	Sepsis (Septicemia) 10/2020 - 01/2017
4	Splenomegaly 01/2016 - 02/2006
3	Inflammation (Inflammations) 01/2022 - 08/2013
3	Lymphoma (Lymphomas) 01/2022 - 01/2019
3	Glucocorticoid Receptor Deficiency 01/2022 - 07/2014
3	Thrombotic Microangiopathies 12/2021 - 12/2020
3	COVID-19 related pediatric multisystem inflammatory disease 05/2021 - 08/2020
3	Lymphopenia (Lymphocytopenia) 01/2021 - 10/2020
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 03/2014
3	Philadelphia Chromosome 01/2019 - 12/2017
3	Lymphadenopathy 01/2016 - 09/2006
2	Neutropenia 01/2022 - 12/2013
2	Thrombocytopenia (Thrombopenia) 01/2022 - 11/2020
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Vascular System Injuries 12/2021 - 04/2021
2	Fever (Fevers) 10/2021 - 02/2017
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 02/2017
2	Multiple Myeloma 01/2018 - 09/2016
2	Hyperferritinemia 02/2017 - 06/2013
2	Mucositis 01/2017 - 11/2012
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2016 - 10/2012
2	Body Weight (Weight, Body) 10/2014 - 04/2013
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 12/2013 - 07/2005
1	Leukopenia 01/2022
1	Anemia 01/2022
1	Lymphadenitis (Adenitis) 01/2022
1	Histiocytic Necrotizing Lymphadenitis (Kikuchi Disease) 01/2022
1	Castleman Disease (Castleman's Disease) 01/2022

Drug/Important Bio-Agent (IBA)

19	Chimeric Antigen ReceptorsIBA 01/2022 - 04/2013
17	CytokinesIBA 01/2022 - 01/2008
11	Sirolimus (Rapamycin)FDA Link 01/2020 - 09/2006
8	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2014
7	tocilizumab (atlizumab)FDA Link 01/2022 - 04/2013
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2015
7	tisagenlecleucelIBA 01/2022 - 04/2013
6	AntibodiesIBA 01/2021 - 01/2008
6	Phosphotransferases (Kinase)IBA 01/2020 - 08/2012
5	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2016
4	GlucocorticoidsIBA 01/2022 - 01/2020
4	Pharmaceutical PreparationsIBA 01/2018 - 07/2014
3	InterferonsIBA 01/2022 - 02/2014
3	ProteomeIBA 01/2022 - 04/2021
3	Immunoglobulin G (IgG)IBA 05/2021 - 01/2008
3	ruxolitinibIBA 01/2021 - 10/2012
3	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 09/2008
3	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 03/2010
3	TOR Serine-Threonine KinasesIBA 01/2014 - 06/2009
3	MTOR InhibitorsIBA 10/2012 - 09/2008
2	Bortezomib (Velcade)FDA Link 01/2022 - 09/2016
2	Proteasome InhibitorsIBA 01/2022 - 09/2016
2	EmapalumabIBA 01/2022 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
2	siltuximabIBA 01/2022 - 01/2016
2	ChromatinIBA 06/2021 - 07/2014
2	Interleukin-8 (Interleukin 8)IBA 01/2021 - 01/2020
2	Imatinib Mesylate (Gleevec)FDA Link 01/2021 - 01/2018
2	Fibrinogen (Factor I)FDA Link 01/2021 - 01/2018
2	Complement System Proteins (Complement)IBA 12/2020 - 01/2020
2	Biological ProductsIBA 10/2020 - 09/2013
2	nelarabine (506U78)FDA Link 10/2020 - 01/2020
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2019 - 08/2012
2	MLN 8237IBA 01/2019 - 11/2012
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2018
2	Monoclonal AntibodiesIBA 01/2018 - 08/2007
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2017 - 01/2014
2	Alkaline PhosphataseIBA 01/2017 - 11/2012
2	InterleukinsIBA 03/2014 - 02/2014
2	Rituximab (Mabthera)FDA Link 08/2013 - 08/2007
1	CytosineIBA 11/2022
1	palbociclibIBA 01/2022
1	SEC Translocation ChannelsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	tofacitinibIBA 01/2022
1	ribociclibIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	Asparaginase (Elspar)FDA Link 01/2022
1	Interferon Type IIBA 01/2022
1	GlutaminaseIBA 01/2022
1	Glutamine (L-Glutamine)FDA Link 01/2022

Therapy/Procedure

38	Therapeutics 01/2022 - 02/2006
14	Drug Therapy (Chemotherapy) 01/2022 - 08/2007
9	Immunotherapy 01/2022 - 02/2014
2	Critical Care (Surgical Intensive Care) 11/2020 - 02/2017
2	Transplantation 01/2020 - 01/2018
2	Hematopoietic Stem Cell Transplantation 01/2019 - 11/2013